Search This Blog

Sunday, May 28, 2017

Practical Guide 2017

Practical Guide 2017




Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

Here is an exchange, a rather bad one ... One says:
This is called 'close the door behind you', much like former immigrants opposing ... immigration. And there is worse: each and every one has his own restrictions, taboos: according to them, descalation is not for you if CD4 are less than ... If your CD4/CD8 ratio is less than ... If your reservoir is... If your combo is not X or Y ... Etc. All this is rigorously FALSE!

Without an informed, well-argued deciphering, it sparks in all directions: this is all FAKE-NEWS

A Practical Guide to Avoid Misunderstanding


Update of the Practical Guide SAFE 4/7: ANRS-4D introduces a PREMIUM eligibility and the Morlat 2016-2017 report explicitly authorizes ICCARRE, without any practical information, without citing all the trials, which would have been useful and honest. There is a great advantage: by saying nothing, it saves us the usual bullshit! Pr Rouzioux-of-criteria ate her hat!

The Morlat report is the usual useful idiot, silly and useless, unusable and unpractical. The reader, patient or doctor, is referred to just 2 trials, without the least bibliographic reference to ICCARRE. Morons!

Allègement thérapeutique vih iccarre guide ANRS-170-Quatuor arabe anglais afrique
This suits me a little, the patient searches on the internet and invariably gets to the Practical Guide, a very downloaded document, and for medical advise, on our list of doctors. She's out of trouble! Good!

The Practical Guide is enriched accordingly. It is available in French, English, Portuguese, Spanish (soon) and Arabic (indeed. It is not claimed to be perfect, nor to be a substitute to a doctor, expert-in-that-very-matter (Beware of incapable, ignorant, incompetent or liars and ... counterfeits)

The 2016 version differs from the 2015 version:


ANRS-4D revolutionizes the short cycle; The 2016 version therefore differs from the 2015 version:
- Eviplera® (Complera®) is tested: 100% successful
- Premium eligibility: Short Cycle is more appealing
- Direct to 4/7, under eligibility conditions: validated
- In patients, strictly eligible and strictly observant, the VL has never picked up: in this context, our rule of frequent VL can reasonably be reconsidered (even if I keep liking it, but I am incapable to prove it is indispensible

Looking at at the rare (very very rare ...) personal testimonies of failures, one inevitably finds failure to follow of one of the three rules: Efficiency, progressivity, frequent VL. And Shit happens ... Well, always easy repaired (eg back to 7/7) ...

Premium Eligibility


Progressivity: Well ... I prefer progressivity, because I went through the anguish of 6/7 (I was scared!). Perhaps useless, it did not cost me.

Frequent VLs: People have trouble with this; VLs detect a loss of efficiency as soon as possible. It is the other side of the efficiency coin. If one is sure of the efficacy, very sure, what about the need for frequent VLs (month-1, m-2, m-4, m-6 ...)? Okay... But true efficiency is proved with ... VL!

Efficiency: many presume drug's efficiency ... Yes, they have been given the latest very modern, very pricey, so well marketed that they neglected all warnings. This medicine, imperfect, is better sent to the sewer. ANRS-4D formalizes the Premium eligibility, which is already in ICCARRE (if you can decypher), not in the others, an additional proof that ICCARRE is not a simple sequel.

conditions Simple Eligibility Premium Eligibility
a priori efficiency validation No Yes (genotype required)
validation of usage efficacy
 
2 successives UD VL
 
3 times VL < 50
(make sure it is undetectable)
minimal duration of current ART 12 months 4 months
Advantages
 
no Genotype
 
4/7 direct
frequent VL unnecessary?
disadvantages 6/7, 5/7; frequent VL Genotype required or redone


ICCARRE method of to redo a genotype or regain sensitivity is stunning! It is a Septist's nightmare and,therefore a good reason to explore it! And we'll get back to it!

What about ANRS-170-Quatuor?


Announced for the end of 2016, then by act-up for July 2017, it will be good enough if it ever starts one day! We are being put off. Results for 2020! At best ... Well ... I hope noone is fooled by this little game.

It is merely the continuation of the ANRS-4D trial, which coordination had been entrusted to Mmes BENALYCHERIF and AMAT (phone: +33 (0)1 40 25 63 65, email: aida.benalycherif... followed the at sign then by ...gmail.com et karine.amat... followed the at sign then by ...hotmail.fr). You should be able to find more there.

Morlat already authorizes ICCARRE, then, what is the point with ANRS-170-Quatuor? What's the point?

This blog is not a medical advice: For this strategy, see Dr. de Truchis (see list). What about others? Well ... Why the copy when we have the original? Ignore the ignorant, and go to one of these docs, Practical Guide in hand. Move your ass! And report!

Today, is the first of Ramadan: our elders have understood the benefit of 'breaks', also of the Shabbat breaks. Since Copernicus, we have a much better understanding of rhythms! Good Ramadan to those who celebrate it, and Good Shabbat and Good fuck to all the others!



Our readership explodes: we have new projects, we need help! we are looking for translators and also voices for podcasts. Someone to animate via social networks would also be of great help! You like this blog, so, please help!


This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.